The mechanism of action was that the vaccine promoted the expression of the surface molecules CD40, CD80, and CD86 of DCs, allowing DCs to efficiently present antigens to T cells, enhancing the proliferation and activation of CD4+ and CD8+ T cells in mice and delaying tumor growth. Here, CD8A is linked to neoplasm.